High visit-to-visit blood pressure variability predicts global cognitive decline: The Multi-Ethnic Study of Atherosclerosis

George D. Daniel¹,² | Haiying Chen³ | Alain G. Bertoni⁴ | Timothy M. Hughes⁴,⁵ | Kathleen M. Hayden⁶

¹Department of Neurobiology and Anatomy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
²Department of Psychology, Howard University, Washington, DC, USA
³Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
⁴Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
⁵Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
⁶Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

Correspondence
Kathleen M. Hayden, Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd. Winston-Salem, NC 27157, USA.
Email: khayden@wakehealth.edu

Abstract
Background: Research of hypertension-related risk factors for Alzheimer’s disease has typically focused on blood pressure (BP) levels, despite evidence that high blood pressure variability (BPV) over time may predict poorer cardiovascular, neuropathological, and neurocognitive outcomes. We evaluated associations between BPV and cognitive function in the Multi-Ethnic Study of Atherosclerosis (MESA).

Methods: Multivariable linear and logistic regression analyses of BP data across six examinations were used to determine associations that BPV (average real variability [ARV], variability independent of the mean [VIM]) and group-based latent BP trajectories have with cognitive function, decline, and impairment, measured by the Cognitive Abilities Screening Instrument (CASI), Digit Symbol Coding (DSC), and Digit Span tests.

Results: Participants (N = 1314; mean baseline age = 57) were 50% female, and 48% White. Higher systolic (β = −0.06, 95% confidence interval [CI]: −0.12, −0.0001) and diastolic (β = −0.08, 95% CI: −0.14, −0.02) ARV predicted increased global cognitive decline after covariate adjustment. Stronger relationships between BPV and global cognition were in older, White and Black participants, apolipoprotein E (APOE) ε4 non-carriers, male participants, and non-antihypertensive medication users.

Conclusion: Results suggest that higher systolic and diastolic BPV is an independent risk factor for cognitive dysfunction and decline in this multi-ethnic cohort. This relationship differs across demographic and clinical characteristics.

KEYWORDS
blood pressure, blood pressure measurement/monitoring cognitive impairment, ethnicity, race

1 | INTRODUCTION

Vascular disorders in midlife increase the risk for late-life cognitive dysfunction and dementia.¹⁻⁷ In the Multi-Ethnic Study of Atherosclerosis (MESA), we have shown previously that higher baseline blood pressure (BP) and its change over time are associated with poorer performance on tests of global cognitive performance, processing speed, and working memory.⁴

Blood pressure (or BP) can fluctuate across examinations in response to intrinsic regulatory mechanisms and extrinsic...
environmental and behavioral factors like poor drug adherence, uncontrolled hypertension, and aging.8,9 High blood pressure variability (BPV) has been explored as a risk factor for cognitive impairment.10–13 The Atherosclerosis in Communities (ARIC) study13 demonstrated that higher long-term systolic BP (SBP) and diastolic BP (DBP) variability is associated with lower global cognition in later life, but not with cognitive decline, whereas the China Health and Nutrition Survey12 observed an association between high BPV and increased global cognitive decline. BPV has been associated with impaired cognitive function across domains and with adverse neurophysiological changes, such as tau accumulation, white matter lesions, and decreased hippocampal volume.10,11,14–16 BP control interventions have shown promise in reducing the risk of mild cognitive impairment (MCI) and incident dementia, but have typically been focused on lowering BP levels rather than BPV.17,18

There are racial/ethnic differences in BP that may affect the relationship between BP and cognition, including differences in hypertension prevalence, management, and control,19,20 and in dementia risk, which is modified by hypertension status.21 Few studies have investigated the impacts of race/ethnicity on the relationship between BPV and cognition. Tsang et al. found that diastolic BPV correlated with incidental and verbal memory but not global cognition in a cross-sectional study of Black participants.22 The ARIC study did not find significant differences between Black and White participants in the association between BPV and cognition.7 Although this relationship has been investigated in diverse international settings and cultural groups, few studies have the ability to directly compare multiple racial and ethnic groups within the United States to examine the presence of heterogeneity of effects.

We expand upon prior MESA studies by conducting longitudinal analyses studying the influence of BPV in midlife on cognition in advanced age. We investigate potential modifiers of the relationship of BPV with cognition, race/ethnicity, sex, apolipoprotein E (APOE) ε4 carrier status, and anti-hypertensive (AHT) medication use.7,10,23,24 BP trajectory analyses will demonstrate underlying differences in the shape of change, which have previously predicted negative cardiovascular disease (CVD) and neurocognitive outcomes.25–28 To our knowledge, group-based trajectories have not been used to address the relationship of midlife BP with late-life cognitive functioning. This data-driven approach may provide valuable information regarding the shape and direction of BP change and offers advantages over “naïve approaches” to trajectory analyses by empirically defining the characteristics of trajectory groups.29

1.1 Expected outcome

We hypothesized that increased BPV would predict poorer cognitive performance, cognitive decline, and impairment, and that these findings would differ according to demographic and genetic risk groups. It is expected that BP trajectory groups would differentially predict cognitive performance.

---

### RESEARCH IN CONTEXT

1. **Systematic Review**: The authors conducted an extensive search of standard resources such as PubMed and found a number of longitudinal observational studies investigating the relationship between blood pressure variability (BPV) and dementia-related cognitive dysfunction or decline. These studies largely indicate poorer cognitive performance associated with increased BPV, but often lacked observed relationships with cognitive decline, or in multi-ethnic US cohorts.

2. **Interpretation**: In the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, long-term BPV is an independent modifiable risk factor for dementia-related cognitive decline. This effect is largely consistent across racial/ethnic groups, and is likely influenced by heterogeneous underlying BP trajectories.

3. **Future Directions**: Future directions include: (1) further research into this relationship with larger Hispanic and Chinese American samples; (2) larger overall sample to better investigate individual BP trajectory groups; (3) more detailed cognitive and neurobiological measures; and (4) more detailed assessment of anti-hypertensive (AHT) medication types for potential effect moderation.

---

### METHODS

#### 2.1 Study design and participants

All MESA participants provided informed consent prior to participation and protocols were approved by local institutional review boards. MESA recruited participants who were free of CVD to investigate the longitudinal progression of subclinical to clinical CVD in a multi-ethnic population.30 The study collected cardiovascular measures over six examinations spanning nearly 20 years with a mean of 3.11 years between each exam for our sample (Baseline/Exam 1 [2000–2002], Exam 2 [2002–2004], Exam 3 [2004–2005], Exam 4 [2005–2007], Exam 5 [2010–2012], and Exam 6 [2016–2018]). Brief cognitive assessments were administered at Exam 5 and again at Exam 6. BPV measures and BP trajectories were derived from a sample of 6066 participants with three or more BP measures from the first five exam visits. Participants who met BP measurement requirements and participated in cognitive testing at Exams 5 and 6 were included in the analytic sample. Participants with invalid or incomplete cognitive abilities screening instrument (Cognitive Abilities Screening Instrument [CASII]) scores, who had a stroke during the study period, had a diagnosis of dementia prior to Exam
5, or were missing relevant regression model covariate data were excluded.

2.2 | Blood pressure measures

BP measures at each examination were collected using standardized procedures. Resting, seated BP was measured in the right arm with the Dinamap model Pro 100 automated sphygmomanometers. Participants underwent three consecutive BP measurements, and the last two were averaged to create final analysis measures. Details of MESA measures have been described previously.13 Average real variability (ARV) was calculated to account for the order of the clinic visits in which BP was measured, and was measured using the “average of the absolute differences between consecutive BP readings” across visits.31,32 Variability independent of the mean (VIM) was calculated to measure random dispersal of BP levels and does not correlate with BP mean, enabling the analysis of BPV independently from the BP mean.13

BP trajectories were derived using group-based trajectory modeling.33,34 These models demonstrate the patterns and shape of BP change from Exams 1 to 5, irrespective of AHT medication use. The maximum number of potential groups for these models was obtained from a combination of prior knowledge and the use-of-fit statistics. Previous BP trajectory studies suggested that the maximum number of possible systolic (SBP) and diastolic (DBP) trajectory groups would be six and five, respectively.25,27 We sequentially derived BP models with increasing number of groups until this maximum was reached. We used Bayesian information criteria (BIC) values to fit the number of groups and individual group shape over time.33,34 The minimum threshold for posterior probability of group membership (>0.7)34 and group size considerations29 were utilized with BIC values to determine final models.

2.3 | Cognitive measures

Data from three neurocognitive tests serve as outcome measures and have been described in detail previously.35 The CASI, Digit Span forward and backwards (DS), and Digit Symbol Coding (DSC) tests were used to assess global cognitive function, working memory and attention, and processing speed, respectively.36–38 The CASI was developed for use in multi-cultural populations. Invalid CASI scores were determined by test administrators, technically invalid scores (<5), and incomplete examinations.4

Cognitive performance was assessed at Exams 5 and 6, and for change between these. Standardized z-scores for each test were calculated using means and standard deviations from Exam 5. Change in z-score from Exam 5 to Exam 6 was used to denote change in the CASI, DS, and DSC tests. Low global cognitive functioning (LCF) has been utilized previously in MESA4 as a measure of cognitive impairment based on CASI score distribution. Individuals in the bottom 10th percentile of each age-, education-, and race-stratified CASI distribution at Exams 5 and 6 were assigned the status of LCF.

2.4 | Additional measures

Questionnaires were used to gather demographic data, tobacco and alcohol use, medical conditions and medication use, and moderate and vigorous physical activity total (metabolic equivalents- minutes per week [MET-MIN/WK]).30 Education was categorized into four strata (≥HS Graduate, Some College or Technical/Associate Degrees, College Graduate [Bachelor’s], Graduate/Professional). Smoking intensity was defined as the average number of cigarettes smoked per day. Participants’ height and weight was assessed for the calculation of body mass index (BMI; kg/m2) and total cholesterol and glucose were measured in blood samples taken after a 12-hour fast. Diabetes was defined as fasting glucose ≥7 mmol/L (≥126 mg/dL) or use of hypoglycemic medication. Impaired fasting glucose was 6.11 to 7 mmol/L (≥100 mg/dL to 126 mg/dL). Hypertension was SBP over 140 mmHG or DBP over 90 mmHG, or use of AHT medications. Depressive symptoms were measured using the Center for Epidemiologic Studies Depression Scale (CES-D); scores of 16 or higher indicated the presence of depressive symptoms. Participants excluded from the analysis had dementia defined by an International Classification of Diseases, Ninth Revision (ICD-9) code documented history of dementia, or a report of taking memory medications. Stroke diagnoses were determined using ICD-9 codes.

2.5 | Statistical analysis

Analyses were conducted using SAS 9.4 Software. Two-sample t-tests and chi-square tests determined differences between those included and excluded from our sample. Means and SDs, or percentages, were reported for baseline characteristics, and chi-square tests and analyses of variance (ANOVARs) determined differences in these characteristics by race and ethnicity. Correlation analyses showed relationships of BP and each BPV index with one another. ANOVARs and correlations demonstrated associations between ARV and baseline characteristics. Multivariable linear and logistic regression models determined relationships between BPV indices and cognition using sequentially adjusted models. The first model was unadjusted. A partially adjusted model included baseline age, education level, sex, race/ethnicity, APOE ε4 carrier status, and study center. Fully adjusted models accounted for Exam 1 characteristics: age, education level, sex, race/ethnicity, APOE ε4 carrier status, study center, and country of birth; and Exam 5 characteristics: income, household size, smoking intensity, depressive symptoms, BMI, glucose, AHT and diabetes medications, and mean SPB or DBP (from visits 1–5). Associations of BPV with Exam 6 outcomes and cognitive change were further adjusted for the time interval between Exams 5 and 6, and the interaction of either SBP or DBP mean with the time between Exams 5 and 6. Stratified analyses were
conducted where significant interaction terms ($P < .05$) were identified for race, age, sex, APOE ε4 status, or AHT medication use.

We used sequentially adjusted multivariable linear and logistic regressions to determine the differential associations between BP trajectory groups, using the lowest BP group as a reference, with each cognitive measure. The first model was unadjusted and a second, fully adjusted, model accounted for age, sex, APOE ε4 carrier status, education, and race/ethnicity at baseline, and glucose, BMI, and presence of AHT medication at Exam 5. In sensitivity analysis, another model contained covariates from the fully adjusted models of BPV and cognition. Inverse probability of attrition weighting was used to account for participant dropout and potential selection bias.39,40

3 | RESULTS

A total of 6814 participants were enrolled at MESA Exam 1 (Figure 1). Of these, 748 participants who did not have three or more BP measures were excluded from the analysis ($n = 6066$). A total of 3303 participants returned for Exam 6 and 2048 completed cognitive assessments; 1985 of those had cognitive data from Exams 5 and 6. A further 142 participants were excluded with invalid CASI scores ($n = 1843$). Finally, 529 were excluded because of ICD-9 codes for dementia or memory medication use before cognitive testing, stroke diagnosis throughout the study period or missing regression covariate measures, leaving an analytic sample size of 1314 participants representing four racial/ethnic groups.

Participants in our sample were younger (58 vs 63 years), had more education, were wealthier, and were healthier, including lower BPV and better cognitive scores, than excluded participants (Table S1). Table 1 shows the baseline characteristics of the sample by race/ethnic groups. Demographics, health behaviors, clinical characteristics, and BP measures differed significantly between race/ethnic groups. Black and Hispanic groups generally had higher BPV and were disproportionately represented in higher BP trajectory groups. At the time of the first cognitive assessment, the average age was 66.7 (8.3) years.

BPV differed by age, income, physical activity, cardio-metabolic diseases, and BP trajectory groups (Tables S2,S3). Group-based trajectory modeling criteria were used to select BP trajectories models with five SBP groups and four DBP groups (Figures 2 and 3). Systolic trajectory groups 1 to 5 can be described as low-normal stable, normal stable, high-normal stable, hypertensive-increasing, and hypertensive-decreasing, respectively. Diastolic groups 1 to 4 all showed moderate decline across the study period and were numbered sequentially from low to high normal BP.

Because of the high degree of collinearity between systolic ($R^2 = 0.76$) and diastolic ($R^2 = 0.80$) ARV and VIM, and because VIM cannot be compared across study populations because of its reliance on cohort BP distribution,13 ARV served as the primary exposure variable and VIM was reserved for sensitivity analyses. Table 2 displays unadjusted and fully adjusted models of ARV and cognition. Increased systolic ($\beta = -0.06$, 95% confidence interval [CI]: $-0.12$, $-0.0001$) and diastolic ($\beta = -0.08$, 95% CI: $-0.14$, $-0.02$) BPV were predictive of increased global cognitive decline from Exams 5 to 6 in fully adjusted models. These results were nearly identical in partially adjusted models (results not shown), indicating that differences in unadjusted and fully adjusted models were due largely to adjustment for age, sex, education, race/ethnicity, APOE ε4 carrier status, and study site. Increased systolic ($\beta = -0.06$, 95% CI: $-0.11$, $-0.004$) and diastolic ($\beta = -0.10$, 95% CI: $-0.15$, $-0.04$) VIM were associated with increased global decline but also with higher global performance at Exam 5 ($\beta = 0.06$, 95% CI: $0.004$, $0.10$).

Fully adjusted sensitivity analyses of ARV with global cognitive functioning at Exam 6 were stratified by age, and analyses of ARV with
| TABLE 1 | Clinical/demographic characteristics, BPV, and cognition by race/ethnicity |
|---------|-------------------------------------------------------------------------|
|         | **White** *(N = 636)* | **Chinese** *(N = 89)* | **Black** *(N = 381)* | **Hispanic** *(N = 208)* | **Overall** *(N = 1314)* |
|         | Mean (SD)/ (%) | Mean (SD)/ (%) | Mean (SD)/ (%) | Mean (SD)/ (%) | Mean (SD)/ (%) | P-value |
| Age (years) | 57.36 (8.28) | 57.30 (8.84) | 57.52 (8.45) | 56.85 (8.69) | 57.32 (8.43) | .83 |
| Sex (female) | 50.63% | 37.08% | 55.38% | 41.35% | 49.62% | <.001 |
| APOE ε4 (at least 1 copy) | 23.90% | 12.36% | 35.43% | 23.08% | 26.33% | <.001 |
| Education | <.001 |
| < HS Grad | 12.11% | 25.84% | 17.85% | 33.65% | 21.39% |
| Some college | 26.42% | 16.85% | 39.90% | 30.82% |
| College grad | 27.83% | 26.97% | 19.95% | 21.92% |
| Post grad | 33.65% | 30.34% | 22.31% | 25.88% |
| No health insurance | 2.99% | 16.85% | 5.51% | 14.42% | 6.47% | <.001 |
| Income (< $25,000) | 8.65% | 26.97% | 18.37% | 35.10% | 16.89% | <.001 |
| Birth place (U.S.) | 93.08% | 8.99% | 90.03% | 40.38% | 78.16% | <.001 |
| Number in household | 2.18 (1.13) | 2.99 (1.31) | 2.12 (1.19) | 2.60 (1.44) | 2.29 (1.23) | .001 |
| Ever smoker (yes) | 7.08% | 5.62% | 11.29% | 5.29% | 8.14% |
| Average cigs smoked/day | 10.09 (14.14) | 4.49 (9.94) | 8.13 (11.21) | 5.71 (10.24) | 8.45 (12.64) | <.001 |
| MV physical activity | 5457.46 (4937.82) | 4428.99 (4304.62) | 7120.31 (6974.33) | 8759.38 (8199.73) | 6392.63 (6279.90) | <.001 |
| CES-D | 7.56 (7.25) | 7.33 (6.86) | 7.28 (6.83) | 8.34 (7.95) | 7.58 (7.22) | .38 |
| BMI | 27.61 (5.17) | 23.76 (3.02) | 30.08 (5.52) | 29.63 (4.95) | 28.39 (5.39) | <.001 |
| Hypertension | 26.42% | 25.84% | 39.90% | 33.65% | 30.82% |
| AHT medication | 24.06% | 22.47% | 39.63% | 24.04% | 28.46% | <.001 |
| Diabetes medication | 2.36% | 6.74% | 6.56% | 9.13% | 4.95% | <.001 |
| Diabetes | 3.3% | 7.87% | 9.19% | 10.58% | 6.47% | <.001 |
| Glucose | 88.84 (19.33) | 95.54 (16.57) | 93.90 (24.77) | 97.51 (29.61) | 92.14 (22.9) |
| BPV measures | Mean (SD)/ No. (%) | Mean (SD)/ No. (%) | Mean (SD)/ No. (%) | Mean (SD)/ No. (%) | Mean (SD)/ No. (%) |
| Average BP | <.001 |
| SBP | 116.72 (14.42) | 119.59 (13.96) | 125.34 (15.22) | 121.17 (17.35) | 120.12 (15.55) |
| DBP | 68.63 (8.25) | 71.28 (7.43) | 72.61 (8.17) | 70.81 (8.72) | 70.31 (8.42) |
| VIM | <.001 |
| SBP | 10.70 (5.11) | 9.67 (4.36) | 11.39 (5.36) | 10.32 (5.54) | 10.77 (5.22) | .01 |
| DBP | 5.39 (2.55) | 5.02 (2.22) | 5.56 (2.66) | 5.32 (2.59) | 5.40 (2.57) | .30 |
| ARV | <.001 |
| SBP | 14.70 (8.45) | 13.67 (7.73) | 18.05 (10.93) | 15.99 (10.87) | 15.82 (9.70) |
| DBP | 7.56 (3.70) | 7.20 (3.26) | 8.33 (4.39) | 7.99 (4.42) | 7.83 (4.02) | .01 |
| SBP Groups | <.001 |
| Group 1 | 32.39% | 25.84% | 13.39% | 25.96% | 25.42% |
| Group 2 | 46.86% | 49.44% | 49.87% | 44.71% | 47.56% |
| Group 3 | 17.92% | 21.35% | 28.35% | 21.15% | 21.69% |
| Group 4 | 1.89% | 1.12% | 5.25% | 4.81% | 3.27% |
| Group 5 | 0.94% | 2.25% | 3.15% | 3.37% | 2.05% |
| DBP groups | <.001 |
| Group 1 | 17.45% | 10.11% | 7.09% | 10.58% | 12.86% |
| Group 2 | 41.67% | 37.08% | 33.08% | 41.35% | 38.81% |
| Group 3 | 35.06% | 43.82% | 45.41% | 35.10% | 38.66% |
| Group 4 | 5.82% | 8.99% | 14.44% | 12.98% | 9.67% |
TABLE 1 (Continued)

| Cognitive measures | Mean (SD)/No. (%) | Mean (SD)/No. (%) | Mean (SD)/No. (%) | Mean (SD)/No. (%) | Mean (SD)/No. (%) | P-value |
|--------------------|------------------|------------------|------------------|------------------|------------------|---------|
| CASI               |                  |                  |                  |                  |                  |         |
| Exam 5             | 93.24 (4.87)     | 88.52 (6.05)     | 89.17 (6.26)     | 85.88 (8.10)     | 90.58 (6.59)     | <.001   |
| Exam 6             | 93.35 (5.78)     | 89.58 (6.34)     | 89.28 (6.63)     | 86.18 (8.12)     | 90.78 (7.02)     | <.001   |
| Change             | 0.01 (0.76)      | 0.13 (0.77)      | 0.01 (0.74)      | 0.04 (0.89)      | 0.03 (0.78)      | .58     |
| DS                 |                  |                  |                  |                  |                  |         |
| Exam 5             | 17.30 (4.23)     | 18.17 (4.66)     | 15.44 (3.91)     | 12.77 (4.06)     | 16.11 (4.47)     | <.001   |
| Exam 6             | 16.72 (4.10)     | 17.39 (4.34)     | 14.84 (3.56)     | 12.20 (3.32)     | 15.50 (4.20)     | <.001   |
| Change             | −0.13 (0.75)     | −0.16 (0.86)     | −0.14 (0.66)     | −0.13 (0.66)     | −0.13 (0.72)     | .98     |
| DSC                |                  |                  |                  |                  |                  |         |
| Exam 5             | 61.68 (14.23)    | 61.66 (17.45)    | 51.04 (15.50)    | 47.79 (18.04)    | 56.27 (16.65)    | <.001   |
| Exam 6             | 58.16 (16.03)    | 56.02 (18.23)    | 47.46 (15.11)    | 40.13 (18.40)    | 52.13 (17.68)    | <.001   |
| Change             | −0.19 (0.63)     | −0.36 (0.57)     | −0.22 (0.60)     | −0.44 (0.65)     | −0.26 (0.63)     | <.001   |
| LCF Exam 5         | 3.62%            | 7.87%            | 3.67%            | 6.37%            | 4.41%            | .09     |
| LCF Exam 6         | 9.43%            | 12.36%           | 8.92%            | 7.21%            | 9.13%            | .54     |

Note: Average cigarettes smoked per day includes both smokers and non-smokers; hypertension defined as an SBP greater than 140 mm HG and/or DBP greater than 90 mm HG.

Abbreviations: AHT, anti-hypertensive; ARV, average real variability; BMI, body mass index; CASI, Cognitive Abilities Screening Instrument; CES-D, Center for Epidemiologic Studies Depression Scale; DBP, diastolic blood pressure; DSB, digit span backwards; DSF, digit span forward; DSC, digit symbol coding; HS, high school; LCF, low global cognitive functioning; MV physical activity, moderate and vigorous physical activity; SD, standard deviation; SBP, systolic blood pressure; VIM, variability independent of the mean.

**FIGURE 2** Long-term systolic blood pressure trajectory groups during Exams 1 to 5 (2000–2012). Systolic trajectory groups 1 to 5 can be described as low-normal stable (red), normal stable (green), high-normal stable (blue), hypertensive-increasing (black), and hypertensive-decreasing (yellow), respectively.

Global cognitive decline were stratified by age, race/ethnicity, APOE ε4 carrier status, sex, and AHT medication use, all of which interacted with these relationships at a $P < .05$ level. In older participants (≥65 years at baseline), increased systolic ($\beta = −0.11$, 95% CI: −0.23, −0.001) and diastolic ($\beta = −0.13$, 95% CI: −0.24, −0.03) BPV predicted decreased global performance (Table S4). Increased systolic ($\beta = −0.15$, 95% CI: −0.27, −0.03) and diastolic BPV ($\beta = −0.21$, 95% CI: −0.32, −0.09) predicted increased global cognitive decline in older participants. High systolic ($\beta = −0.12$, 95% CI: −0.22, −0.04) and diastolic ($\beta = −0.18$, 95% CI: −0.21, −0.05) BPV were associated with increased global cognitive decline for White participants in stratified analyses, and high diastolic BPV was associated with increased global decline for Black participants ($\beta = −0.12$, 95% CI: −0.22, −0.01) (Table S5). Higher diastolic BPV predicted increased cognitive decline in male ($\beta = −0.10$, 95% CI: −0.18, −0.02) and marginally reduced decline in female ($\beta = −0.08$).

**FIGURE 3** Long-term diastolic blood pressure trajectory groups during Exams 1 to 5 (2000–2012). Diastolic groups 1 to 4 all showed moderate decline across the study period and were numbered sequentially from low to high normal BP: low (red), low-normal (green), normal (blue), and high-normal (black).

predicted increased global cognitive decline in older participants. High systolic ($\beta = −0.12$, 95% CI: −0.22, −0.04) and diastolic ($\beta = −0.18$, 95% CI: −0.21, −0.05) BPV were associated with increased global cognitive decline for White participants in stratified analyses, and high diastolic BPV was associated with increased global decline for Black participants ($\beta = −0.12$, 95% CI: −0.22, −0.01) (Table S5). Higher diastolic BPV predicted increased cognitive decline in male ($\beta = −0.10$, 95% CI: −0.18, −0.02) and marginally reduced decline in female ($\beta = −0.08$,}
95% CI: −0.16, 0.002) participants. Higher systolic (β = −0.07, 95% CI: −0.14, −0.001) and diastolic (β = −0.08, 95% CI: −0.14, −0.001) BPV was associated with increased global cognitive decline in APOE ε4 non-carriers (Table S6). Increased diastolic BPV predicted reduced global performance (β = −0.08, 95% CI: −0.15, −0.01) and increased cognitive decline (β = −0.11, 95% CI: −0.19, −0.03) in those not using AHT medication. Age (p-interaction < 0.001) and race (p-interaction < 0.001) significantly interacted with diastolic VIM to predict global cognitive function at Exam 5. Stratified analyses indicated that higher variability in VIM marginally predicted increased CASI scores for White participants (β = 0.08, 95% CI: −0.002, 0.16), but not for Chinese (β = 0.02, 95% CI: −0.18, 0.24), Black (β = 0.05, 95% CI: −0.04, 0.15), or Hispanic participants (β = 0.05, 95% CI: −0.09, 0.19). Higher variability in VIM did not predict CASI scores in either older (β = 0.07, 95% CI: −0.03, 0.17) or younger adults (β = 0.05, 95% CI: −0.01, 0.10). Interactions with VIM to predicted Exam 5 CASI scores were not identified for sex (p-interaction = 0.77), APOE ε4 carrier status (p-interaction = 0.47), or AHT use (p-interaction = 0.36).

Table 3 shows the relative association of each BP trajectory group with each cognitive outcome. After full adjustment, SBP groups were differentially associated with global cognition, executive function, and information processing. SBP groups 4 and 5, hypertensive-increasing and hypertensive-decreasing, respectively, were most consistently associated with decreased performance. DBP group 4, pre-hypertensive and declining, was associated with reduced global cognition and executive function. Adjustment for sensitivity analysis covariates, including BP mean, yielded no diastolic BP group differences in association with cognitive performance. SBP group 4 (β = 0.08, 95% CI: −0.13, −0.03) and group 5 (β = −0.07, 95% CI: −0.12, −0.02) predicted poorer global performance at Exam 6.

Table 4 shows the differential odds of cognitive impairment between BP trajectories. After full adjustment, DBP trajectory group 4 (odds ratio [OR] = 7.51, 1.88–30.00) was associated with increased impairment odds at Exam 5, compared to group 1. After sensitivity analysis covariate adjustment, DBP groups 2 (OR = 3.96, 1.54–10.23; 3: OR = 6.70, 1.59–28.24; and 4: OR = 24.59, 3.01–200.99) were associated with increased odds of cognitive impairment at Exam 6 compared to group 1. The large ORs and wide CIs for DBP group 4 caution the interpretation of these results and may be related to the small size and comparatively large heterogeneity within this group.
### Table 3

Association of BP trajectories with cognitive performance and decline—models 1 and 2

| BP groups | Global cognition (CASI) | Executive function (DS total) | Processing speed (DS coding) |
|-----------|-------------------------|-------------------------------|-------------------------------|
|           | Exam 5 | Exam 6 | Change | Exam 5 | Exam 6 | Change | Exam 5 | Exam 6 | Change |
| **Unadjusted** |         |         |         |        |        |         |        |        |         |
| Systolic   |         |         |         |        |        |         |        |        |         |
| Group 1    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    |
| Group 2    | -0.10  | -0.16  | -0.03   | -0.08  | -0.15  | -0.02   | -0.10  | -0.17  | -0.03   |
| Group 3    | -0.17  | -0.23  | -0.11   | -0.17  | -0.23  | -0.11   | -0.14  | -0.20  | -0.07   |
| Group 4    | -0.12  | -0.18  | -0.07   | -0.18  | -0.23  | -0.13   | -0.14  | -0.20  | -0.09   |
| Group 5    | -0.10  | -0.16  | -0.05   | -0.17  | -0.22  | -0.12   | -0.12  | -0.17  | -0.06   |
| **Diastolic** |         |         |         |        |        |         |        |        |         |
| Group 1    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    |
| Group 2    | -0.11  | -0.19  | -0.02   | -0.10  | -0.15  | -0.02   | -0.001 | -0.09  | -0.08   |
| Group 3    | -0.08  | -0.16  | 0.01    | -0.03  | -0.12  | 0.05    | -0.01  | -0.09  | 0.08    |
| Group 4    | -0.15  | -0.22  | -0.08   | -0.09  | -0.16  | -0.03   | -0.11  | -0.18  | -0.04   |
| **Fully adjusted** |         |         |         |        |        |         |        |        |         |
| Systolic   |         |         |         |        |        |         |        |        |         |
| Group 1    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    |
| Group 2    | -0.02  | -0.08  | 0.05    | -0.02  | -0.08  | 0.05    | -0.02  | -0.09  | 0.05    |
| Group 3    | -0.04  | -0.09  | 0.01    | -0.08  | -0.13  | -0.03   | -0.07  | -0.12  | -0.01   |
| Group 4    | 0.03   | -0.06  | 0.04    | -0.07  | -0.12  | -0.02   | -0.06  | -0.12  | -0.01   |
| **Diastolic** |         |         |         |        |        |         |        |        |         |
| Group 1    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    | 0.00   | 0.00   | 0.00    |
| Group 2    | -0.05  | -0.12  | 0.03    | -0.04  | -0.12  | 0.02    | 0.04   | -0.04  | 0.12    |
| Group 3    | -0.02  | -0.09  | 0.07    | 0.01   | -0.07  | 0.09    | 0.03   | -0.06  | 0.12    |
| Group 4    | -0.08  | -0.14  | -0.02   | -0.04  | -0.11  | 0.02    | 0.03   | -0.04  | 0.11    |

Note: Model 1 is unadjusted for covariates. Model 2 covariates are: age, sex, APOE ε4 carrier status, education, and race/ethnicity at baseline; clinical characteristics at Exam 5: glucose, BMI, and presence of anti-hypertensive medication at Exam 5. Statistical significance was defined as $P < .05^*$, $P < .05^†$, $P < .01^‡$, $P < .001$. Adjusted β's (95% CIs) associated with 1 SD increases of each cognitive parameter are shown. The 1 SD increases of each cognitive outcome are: per 6.59, 7.02, and 0.78 for CASI scores at Exam 5, Exam 6, and CASI Change, respectively; per 4.47, 4.40, and 0.72 for DS scores at Exam 5, Exam 6, and DS Change, respectively; and per 16.65, 17.68, and 0.63 for DSC scores at Exam 5, Exam 6, and DSC Change, respectively. Statistical significance at $P < .05$ level is indicated by bold text.
TABLE 4  Association of BP trajectories with global cognitive impairment

| BP trajectories | Cognitive domain | Unadjusted OR (95% CI) | Fully adjusted OR (95% CI) |
|-----------------|------------------|------------------------|---------------------------|
|                 | Low cognitive functioning | Low cognitive functioning |                 |
|                 | (Exam 5)           | (Exam 6)               |                           |
| Systolic        |                   |                        |                           |
| Group 1 (N = 334) | 1.00             | 1.00                   |                           |
| Group 2 (N = 625) | 1.35 (0.59–3.09) | 1.21 (0.71–2.06)      |                           |
| Group 3 (N = 285) | 3.41* (1.49–7.78) | 2.16† (1.23–3.79)     |                           |
| Group 4 (N = 43) | 4.18† (1.20–14.52) | 4.52‡ (1.96–10.40)    |                           |
| Group 5 (N = 27) | 7.09* (1.99–25.30) | 4.26‡ (1.55–11.68)    |                           |
| Diastolic       |                   |                        |                           |
| Group 1 (N = 169) | 1.00             | 1.00                   |                           |
| Group 2 (N = 510) | 2.73 (0.81–9.19) | 1.42 (0.77–2.62)      |                           |
| Group 3 (N = 508) | 2.03 (0.59–6.99) | 0.84 (0.44–1.61)      |                           |
| Group 4 (N = 127) | 6.31† (1.76–22.65) | 1.16 (0.52–2.59)    |                           |

Note: Adjusted by model 2 covariates: age, sex, APOE ε4 carrier status, education, and race/ethnicity at baseline; clinical characteristics at Exam 5 glucose, BMI, and presence of anti-hypertensive medication at Exam 5. Statistical significance was defined as P < .05*, P < .05†, P < .01‡, P < .001.§

4  DISCUSSION

Higher long-term BP independently predicted global cognitive decline in this relatively healthy, multi-ethnic sample. This relationship may be modified by age, race, sex, AHT medication use, and APOE ε4 carrier status, and is likely influenced by underlying differences in BP trajectories, which differentially predicted cognitive performance.

These results align with similar studies, which have observed relationships between high BPV and cognition. This relationship may be driven by long-term hemodynamic instability and associated microvascular damage, atherosclerosis, and organ hypoperfusion, leading to increased white matter lesions, cortical infarcts, and other neuropathological contributions to cognitive dysfunction. Confidence in these results is strengthened by the consistency of this pattern across ARV and VIM, with VIM indicating an association independent of BP level. Similar effect sizes were observed between systolic ARV and VIM, whereas diastolic VIM appeared to have a somewhat stronger effect. The effect of VIM on cognition was more variable, suggesting that ARV may be a more consistent predictor of cognitive impairment. Further studies are needed to identify the most informative BPV index and mechanistic differences between them.

The finding that BPV is associated with cognitive decline in this younger, healthy and multi-ethnic sample is novel, as studies in the United States generally lack the multiple cognitive measures necessary to make such observations or have reported inconsistent results. BPV-associated cognitive impairments have been observed in bi-racial and young adult samples. However, the current study demonstrates cognitive decline over time, a key criterion for AD in a sample with multiple ethnic groups, an important knowledge gap in this relationship. The lack of association between BPV with other cognitive measures is notable. It has been suggested that this association may be attenuated in healthier populations. This is possible in MESA, which excluded participants with CVD to investigate subclinical cardiometabolic contributions to chronic diseases.

Increased BPV was predictive of increased global cognitive decline among older participants, aligning with studies that found worse BPV-related cognitive outcomes in older age. This differs from studies that showed no modification by age or stronger associations at younger ages, attributed to decreased competing risk factors. The cognitive effects of this risk factor may be most noticeable among older ages, in which cognitive decline is more frequently observed, although BPV likely remains a risk factor for younger populations. The relationship was stronger among those not using AHT medications. Treatments like calcium-channel blockers may reduce BPV and improve BPV-related neurocognitive outcomes in hypertensive patients. Consistent with a previous study of cardio-metabolic relationships with cognition in MESA, the association of BPV and cognitive decline appears stronger in APOE ε4-negative participants, possibly indicating a pathway independent of this genetic risk factor. Similar effect sizes between APOE ε4 carriers and non-carriers, smaller group size for carriers, and potential for APOE as a competing risk factor for BPV caution this interpretation. The stronger effects indicated in men could be explained by generally poorer male cardiovascular health, including higher BPV. However, effect sizes were generally comparable, suggesting common effects across sexes.

Stratified analyses across racial/ethnic groups indicated possible effect modification. Results were largely similar across racial/ethnic groups, with most groups showing a general decrease in global cognitive decline with increased BPV, except for in Chinese participants. These results are similar to those of other studies showing that Black and White participants similarly had poorer cognition with increased BPV, although BPV likely remains a risk factor for younger populations. The relationship was stronger among those not using AHT medications. Treatments like calcium-channel blockers may reduce BPV and improve BPV-related neurocognitive outcomes in hypertensive patients. Consistent with a previous study of cardio-metabolic relationships with cognition in MESA, the association of BPV and cognitive decline appears stronger in APOE ε4-negative participants, possibly indicating a pathway independent of this genetic risk factor. Similar effect sizes between APOE ε4 carriers and non-carriers, smaller group size for carriers, and potential for APOE as a competing risk factor for BPV caution this interpretation. The stronger effects indicated in men could be explained by generally poorer male cardiovascular health, including higher BPV. However, effect sizes were generally comparable, suggesting common effects across sexes.
participants, as similar associations were shown in the China Health and Nutrition Survey.12

BP groups differentially predicted global cognition, executive function, and information processing. Many of these results remained similar after adjustment for mean BP, indicating an independent BPV-related influence cognition. Although the hypertensive-decreasing SBP trajectory (group 5) had a higher mean and BPV than the hypertensive-increasing (group 4), group 4 was more strongly associated with worse cognition, supporting results from the SPRINT trial that indicate that SBP reduction in hypertensive patients may benefit cognitive health.18 These results align with previous findings that higher and more variable BP patterns predict worse cognitive performance.26,28 We expand upon prior work by applying a latent trajectory approach to account for underlying differences in shape and direction of long-term BPV.

This study had several limitations. This is an observational study and we cannot interpret any causative relationships; yet, this analysis provides temporal relationships between BPV over time and change in cognitive performance. Cognitive testing for this sample was not conducted prior to Exam 5, thus we lack cognitive information from the first 10 years of risk factor assessment. Our sample was younger and healthier on average than other studies of cognitive aging due to the MESA study design and our inclusion criteria. Bias may exist in this association due to a higher attrition among participants with poorer health, including those with higher and more variable BP trajectories. This could have reduced the observed effect, as BPV-related cognitive impairment is particularly seen in less healthy populations, although it is possible that those who dropped out with high BPV may have had preserved cognitive abilities. We addressed this bias using inverse probability weighting; there were no significant changes to our results. Observations of spurious associations due to multiple comparisons is possible; however, interdependence of our cognitive and BP measures, and the consistent direction of effects, limits this concern. BP trajectory model development adjusting for AHT medications may be of interest, but their influence could be complex with elements like number, dosage, type, and duration of use potentially influencing trajectories. We chose to derive groups irrespective of other factors, but to adjust for covariates in linear modeling. Relatively small BP trajectory group sizes may have limited the power to detect effects, but do not affect the appropriateness of the models as confirmed using the aforementioned criteria.

5 | CONCLUSION

High visit-to-visit BPV over nearly 20 years is predictive of increased global cognitive decline, independent of mean BP, in this multi-ethnic cohort that was relatively healthy at baseline. This study attempted to address the gaps in knowledge regarding the similarity of this association across multiple ethno-racial groups in the United States, and the results indicate a commonality of effects in BPV-related cognitive decline, after robust adjustment for sociodemographic factors. The observed effects were strongest in participants aged 65 or older at baseline and not using AHT medications. Higher and more variable BP trajectories predicted poorer cognitive performance across multiple domains, highlighting the utility of this method to track underlying differences in the shape of BP change. Future studies should investigate this association with larger samples to investigate differences within heterogeneous ethnic groups and in the relatively small, but high and variable BP trajectory groups.

ACKNOWLEDGMENTS

The authors thank the Multi-Ethnic Study of Atherosclerosis (MESA) participants, other MESA investigators and staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This research was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute (NHLBI), and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). K.M.H. and T.M.H. were supported in part by P30 AG049638, which funds the Wake Forest Alzheimer’s Disease Core Center and the MESA Core. K.M.H. and T.M.H. were also supported in part by R01AG058969. G.D.D. was supported by R25NS089458-05; and T.M.H. was also supported by R01AG054069. The authors (G.D.D., H.C., A.B., T.M.H., and K.M.H.) were involved in the planning, study design, article writing, data analysis, and critical revision of the article. The role of the sponsor, NHLBI, pertained to contract funding of MESA Exams 1 to 6.

CONFLICT OF INTEREST

The authors declare no conflicts of interest. Author disclosures are available in the supporting information.

REFERENCES

1. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254. https://doi.org/10.1001/jamaneurol.2017.1658
2. de Bruijn RF, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med. 2014;12(1):130. https://doi.org/10.1186/s12916-014-0130-5
3. Gillett SR, Thacker EL, Letter AJ, et al. Correlates of incident cognitive impairment in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Clin Neuropsychol. 2015;29(4):466-486. https://doi.org/10.1080/13854046.2015.1042524
4. Hughes TM, Craft S, Baker LD, et al. Changes in metabolic risk factors over 10 years and their associations with late-life cognitive performance: the Multi-Ethnic Study of Atherosclerosis. Alzheimers Dement. 2017;8:18-25.
5. Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function. Hypertension (Dallas, Tex : 1979). 2016;68(6):e67-e94. https://doi.org/10.1161/HYPERTENSIONAHA.113.0147
7. Yuichiro Y, Michael G, Wanmei W, et al. Long-term blood pressure level and variability from midlife to later life and subsequent cognitive change: the ARIC neurocognitive study. J Am Heart Assoc. 2018;7(15):e009578. https://doi.org/10.1161/JAHA.118.009578

8. Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance and application. J Clin Hypertens (Greenwich). 2018;20(7):1133-1137. https://doi.org/10.1111/jch.13304

9. Weber MA. Blood pressure variability and cardiovascular prognosis: implications for clinical practice. Eur Heart J. 2017;38(37):2823-2826. https://doi.org/10.1093/eurheartj/ehx322

10. McDonald C, Pearce MS, Kerr SRJ, Newton JL. Blood pressure variability: clinical relevance and application. J Hypertens. 2014;64(5):1094-1101. https://doi.org/10.1016/j.jhype.2014.04.028

11. Laatzen S, Luzzi S, Provinciali L, Silvestrini M. Blood pressure variability in Alzheimer's disease and frontotemporal dementia: the effect on the rate of cognitive decline. J Alzheimers Dis. 2015;45(2):387-394. https://doi.org/10.3233/JAD-142532

12. Chin B, Viera AJ, Muntner P, et al. Visit-to-visit variability in blood pressure is related to late-life cognitive decline. Hypertension. 2016;68(1):106-113. https://doi.org/10.1161/HYPERTENSIONAHA.116.07494

13. Yano Y. Visit-to-visit blood pressure variability – What is the current challenge? Am J Hypertens. 2017;30(2):112-114. https://doi.org/10.1093/ajh/hpw124

14. Haring B, Liu J, Salmoiraghi-Blotcher E, et al. Blood pressure variability and brain morphology in elderly women without cardiovascular disease. Neurology. 2019;92(12):e1284-e1297. https://doi.org/10.1212/WNL.0000000000007135

15. McDonald C, Pearce MS, Kerr SRJ, Newton JL. Blood pressure variability and cognitive decline in older people: a 5-year longitudinal study. J Hypertens. 2017;35(1):140-147. https://doi.org/10.1097/HJH.000000000001120

16. Sible IJ, Nation DA. Visit-to-visit blood pressure variability and longitudinal tau accumulation in older adults. Hypertension. 2022;79(3):629-637. https://doi.org/10.1161/HYPERTENSIONAHA.121.18479

17. Launer LJ, Hughes T, Yu B, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspectives from the Honolulu Heart Program/Honolulu Asia Aging Study. PLoS Med. 2010;55(6):1352-1359. https://doi.org/10.1161/HYPERTENSIONAHA.109.147389

18. Williamson JD, Pajewski NM, Aachus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. https://doi.org/10.1001/jama.2018.21442

19. Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the National Health and Nutrition Examination Survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017;10(1):e003166. https://doi.org/10.1161/CIRCOUTCOMES.116.003166

20. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci. 2014;348(2):135-138. https://doi.org/10.1097/MAJ.0000000000000308

21. Chen C, Zissimopoulou JM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimers Dement. 2018;4:510-520. https://doi.org/10.1016/j.jctrc.2018.08.009

22. Tsang S, Sperring SA, Park MH, Helenius IM, Williams IC, Manning C. Blood pressure variability and cognitive function among older African Americans: introducing a new blood pressure variability measure. Cogn Behav Neurol. 2017;30(3):90-97. https://doi.org/10.1097/WNN.0000000000000128

23. Andrews S, Das D, Anstey KJ, Easteal S. Interactive effect of APOE genotype and blood pressure on cognitive decline: the PATH through life study. J Alzheimers Dis. 2015;44(4):1087-1098. https://doi.org/10.3233/JAD-140630

24. Kritz-Silverstein D, Laughlin GA, McEvoy LK, Barrett-Conner E. Sex and age differences in the association of blood pressure and hypertension with cognitive function in the elderly: the Rancho Bernardo Study. J Prev Alzheimers Dis. 2017;4(3):165-173. https://doi.org/10.14238/jpad.2017.6

25. Li W, Jin C, Vaidya A, et al. Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: a prospective study. Hypertension. 2017;70(3):508-514. https://doi.org/10.1161/HYPERTENSIONAHA.117.09479

26. Peters R, Peters J, Booth A, Anstey KJ. Trajectory of blood pressure, body mass index, cholesterol and incident dementia: systematic review. Br J Psychiatry. 2020;216(1):16-28. https://doi.org/10.1192/bjp.bp.2019.156

27. Sharashova E, Wilsgaard T, Ball J, et al. Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study. Eur Heart J. 2020;41(16):1554-1562. https://doi.org/10.1093/eurheartj/ehz234

28. Walker KA, Sharrett AR, Wu A, et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA. 2019;322(6):535-545. https://doi.org/10.1001/jama.2019.10575

29. Warren JR, Luo L, Halpern-Manners A, Raymo JM, Palloni A. Do different methods for modeling age-graded trajectories yield consistent and valid results? AJHS. 2015;120(6):1809-1856. https://doi.org/10.1162/ajhs.2015.68162

30. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871-81. https://doi.org/10.1093/aje/kwf113

31. Mena L, Pintos S, Queipo J, Aizpúrua J, Maestre G, Sulbarán T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23(3):505-511. https://doi.org/10.1097/01.hjh.0000160205.81652.5a

32. Pierdomenico SD, Di Nicola M, Esposito AL, et al. Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens. 2009;22(8):842-847. https://doi.org/10.1038/ajh.2009.103

33. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374-393. https://doi.org/10.1177/00491241002903005

34. Nagin D. Group-Based Modeling of Development. Harvard University Press; 2005.

35. Fitzpatrick AL, Rapp SR, Luchsinger J, et al. Sociodemographic correlates of cognition in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Geriatr Psychiatry. 2015;23(7):684-697. https://doi.org/10.1016/j.jagp.2015.01.003

36. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6(1):45-58. https://doi.org/10.1017/S1041610294001602

37. Tsai R-C, Lin K-N, Wu K-Y, Liu H-C. Improving the screening power of the cognitive abilities screening instrument, Chinese version. Dementia Geriatr Cogn Disord. 2004;18(3-4):314-320. https://doi.org/10.1159/000080125

38. Wechsler D. Wechsler Adult Intelligence Scale. Psychological corpora- tion New York; 1955.

39. Mansournia MA, Altman DG. Inverse probability weighting. BMJ. 2016;352:i189. https://doi.org/10.1136/bmj.i189

40. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278-295. https://doi.org/10.1177/0962280210395740
prospective cohort study. BMJ. 2013;347:f4600. https://doi.org/10.1136/bmj.f4600
42. Ma Y, Tully PJ, Hofman A, Tzourio C. Blood pressure variability and dementia: a state-of-the-art review. Am J Hypertens. 2020;33(12):1059-1066. https://doi.org/10.1093/ajh/hpaa119
43. Jia P, Lee HWY, Chan JYC, Yiu KKL, Tsoi KKF. Long-term blood pressure variability increases risks of dementia and cognitive decline: a meta-analysis of longitudinal studies. Hypertension. 2021;78(4):996-1004. https://doi.org/10.1161/HYPERTENSIONAHA.121.17788
44. Lattanzi S, Vernieri F, Silvestrini M. Blood pressure variability and neuropsychological functioning. J Clin Hypertens. 2018;20(4):645-647. https://doi.org/10.1111/jch.13232
45. Yano Y, Ning H, Allen N, et al. Long-term blood pressure variability throughout young adulthood and cognitive function in midlife: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Hypertension. 2014;64(5):983-988. https://doi.org/10.1161/HYPERTENSIONAHA.114.03978
46. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269. https://doi.org/10.1016/j.jalz.2011.03.005
47. Moschetti K, Cummings PL, Sorvillo F, Kuo T. Burden of Alzheimer’s disease-related mortality in the United States, 1999-2008. J Am Geriatr Soc. 2012;60(8):1509-1514. https://doi.org/10.1111/j.1532-5415.2012.04056.x
48. Peng S, Shen T, Liu J, et al. Uncontrolled hypertension increases with age in an older community-dwelling Chinese population in Shanghai. Aging Dis. 2017;8(5):558-569. https://doi.org/10.14336/AD.2016.1220
49. Nardin C, Rattazzi M, Pauletto P. Blood pressure variability and therapeutic implications in hypertension and cardiovascular diseases. High Blood Press Cardiovasc Prev. 2019;26(5):353-359. https://doi.org/10.1007/s40292-019-00339-z
50. Godin O, Tzourio C, Mailard P, Mazoyer B, Dufoüil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation. 2011;123(3):266-273. https://doi.org/10.1161/CIRCULATIONAHA.110.961052

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Daniel GD, Chen H, Bertoni AG, Hughes TM, Hayden KM. High visit-to-visit blood pressure variability predicts global cognitive decline: The Multi-Ethnic Study of Atherosclerosis. Alzheimer’s Dement. 2022;8:e12342. https://doi.org/10.1002/trc2.12342